Signifier Medical Technologies is granted HCPCS Codes
Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
CMS establishes new Level II HCPCS codes to describe eXciteOSA, the first-ever daytime treatment for obstructive sleep apnea
BOSTON, U.S.A., February 22, 2022 (BUSINESS WIRE) — Signifier Medical Technologies LLC, a Boston-based medical technology company, announced today that the Centers for Medicare & Medicaid Services (CMS) established two new Level II Healthcare Common Procedure Coding System (HCPCS) codes to describe eXciteOSA, the first-ever FDA authorized de-novo device for daytime treatment of mild obstructive sleep apnea (OSA) and primary snoring. The CMS coding decision was published on February 16, 2022 and the following codes will become effective on April 1, 2022:
Segulah Medical Acceleration Announces Investment in Allurion Technologies
2022.09.13Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.
Read more
Segulah Medical Acceleration Announces Investment in Navinci Diagnostics
2022.07.12Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.
Read more Signifier Medical Technologies is granted HCPCS Codes
2022.02.28Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
Read more Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies
2021.07.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.
Read more
Segulah Medical Acceleration Announces Investment in SAGA Diagnostics
2021.06.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.
Read more
Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies
2021.06.28Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.
Read more
Blue chip investors back new MedTech investment company
2021.04.29Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.
Read more